ZBH Stock Gains On Q2 Earnings and Revenue Beat, '25 EPS View Up

Zimmer Biomet (ZBH) reported robust second-quarter 2025 results, with adjusted EPS of $2.07 and revenues of $2.08 billion, both surpassing analyst estimates and representing year-over-year increases of 3% and 7% respectively. This strong performance, which led to a 2.2% pre-market share increase, was driven by solid U.S. and international sales and significant growth in its Sports Medicine, Extremities, Trauma (S.E.T.) segment, partially attributed to the Paragon 28 acquisition. Despite a 109 basis point contraction in adjusted operating margin, the company raised its full-year 2025 adjusted EPS guidance to $8.10-$8.30, reflecting confidence in its strategic shift towards higher-growth, diversified segments.

Analysis

Zimmer Biomet (ZBH) reported a robust second quarter for 2025, exceeding consensus estimates with adjusted EPS of $2.07 (+3% YoY) and revenue of $2.08 billion (+7% YoY). The top-line strength was broad-based, with U.S. sales growing 6.1% and international sales rising 8.1%. The key driver of this outperformance was the S.E.T. (Sports Medicine, Extremities, Trauma) segment, which posted impressive 16% growth at constant exchange rates (CER), significantly beating expectations and underscoring the success of the company's strategic focus on higher-growth areas, further supported by the recent acquisition of Paragon 28. This performance from the growth segments helped offset more modest results from the core Knees (+1.8% CER) and Hips (+4.0% CER) businesses. However, this growth came at a cost to profitability, as a 10.5% increase in SG&A expenses contributed to a 109 basis point contraction in the adjusted operating margin to 26.8%. Despite this margin pressure, management signaled strong confidence by raising the full-year 2025 adjusted EPS forecast to $8.10-$8.30, a notable increase from the previous $7.90-$8.10 range and well above the existing consensus of $7.95.

Key Decisions for Investors

• Investors should view the raised full-year EPS guidance and the 16% CER growth in the S.E.T. segment as strong validation of the company's strategic pivot towards higher-growth, diversified medical technology markets.
• It is critical to monitor the company's profitability, as the 109 basis point contraction in adjusted operating margin due to rising SG&A expenses represents a key risk that could offset top-line momentum.
• Given the strong operational beat and positive guidance revision, the article's mention of a Zacks #4 (Sell) rank presents a notable contradiction, warranting further due diligence on valuation or other factors that may not be reflected in the earnings report.